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ABSTRACT 
This study has investigated complexation of fisetin, a natural flavonoid, with three types of 
cyclodextrins to improve its solubility. Sulfobutylether-β-cyclodextrin (SBE-β-CD) showed 
the highest complexation efficiency while maintaining the in vitro antioxidant activity of 
fisetin. Addition of 20 %v/v ethanol in water improved the amount of solubilized fisetin in the 
complex 5.9-fold compared to the system containing water alone. Spray drying of fisetin-
SBE-β-CD complex solution in the presence of ethanol produced a dry powder with improved 
aerosolization properties when delivered from a dry powder inhaler, indicated by a 2-fold 
increase in the fine particle fraction (FPF) compared to the powder produced from the 
complex solution containing water alone. The pitted morphological surface of these particles 
suggested a more hollow internal structure, indicating a lighter and less dense powder. 
Incorporation of 20 %w/w leucine improved the particle size distribution of the powder and 
further increased the FPF by 2.3-fold. This formulation also showed an EC50 value equivalent 
to fisetin alone in the A549 cell line. In conclusion, an inhalable dry powder containing 
fisetin-SBE-β-CD complex was successfully engineered with an improved aqueous solubility 
of fisetin. The dry powder may be useful to deliver high amounts of fisetin to the deep lung 
region for therapeutic purposes.  
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1. Introduction 
Fisetin (3, 3’, 4’, 7-tetrahydroxyflavone) is a flavonoid with antiproliferative, apoptotic, 
antioxidant, anti-inflammatory and neuroprotective activities. In recent years, fisetin has 
attracted widespread interest as many studies have shown its anticancer effect in vitro using 
many cancer cell lines, including lung, colon and prostate cancers [1]. It has shown 
synergistic activities with other anticancer agents (i.e. cisplatin and cyclophosphamide) in 
different carcinoma cell lines [2,3] and acts as an adjunct in cancer therapy to alleviate 
specific adverse effects related to cytotoxic agents or other therapeutics, including protection 
against ovariectomy-induced bone loss in mice [4] and has a renoprotective effect in cisplatin-
induced nephrotoxicity in rats [5]. 
 The low aqueous solubility of fisetin (< 1mg/ml) [6] hinders its delivery; this has led 
to a number of formulation approaches aiming to improve its delivery. Fisetin has been 
formulated in nanoemulsions [6], nanocochleates [7], liposomes [8,9] and cyclosophoroase 
dimer complexes [10].  
 Complexation of fisetin with cyclodextrins has been studied previously to improve its 
solubility. One study found that fisetin could only form a stable complex with β-cyclodextrin, 
but not with the α-cyclodextrin [11]. Complexation of fisetin with another type of 
cyclodextrin (γ-cyclodextrin) was also undertaken in order to understand the behaviour of 
fisetin in the nano-cavity, and confirmed the suitability of the nano-vehicle for parenteral 
administration of fisetin [12]. Another study investigated inclusion of fisetin into β- and γ-
cyclodextrins which resulted in a better aqueous solubility of fisetin and higher cytotoxic 
activity of fisetin against Hela and MC-7 cells [13]. However, none of the studies has yet 
explored the formulation and application of fisetin complex for pulmonary delivery. 
 Sulfobutylether-β-cyclodextrin (SBE-β-CD) is a modified β-CD which has been 
approved by the US Food and Drug Administration (FDA) as a pharmaceutical excipient. Its 
parent form (i.e. β-CD) causes renal toxicity after parenteral administration. Although 
hydroxypropyl-β-cyclodextrin (HP-β-CD) and SBE-β-CD are considered safe at relatively 
high doses for the parenteral route [14], the latter has a safer profile for parenteral delivery, 
with low kidney toxicity and low tendency to cause haemolysis. In general, cyclodextrins that 
are considered to be the safest for parenteral formulation (i.e. γ-CD, HP-β-CD and SBE-β-
CD) are also considered safe for pulmonary application [15]. 
 This study explores the complexation of fisetin with SBE-β-CD with the aim of 
increasing the solubility of the compound. The complex was further engineered into a dry 
  
powder inhaler (DPI) formulation with optimized aerodynamic properties and tested against 
the human lung adenocarcinoma cell line (A549). Compared to other routes, such as oral and 
parenteral, the final DPI preparation will potentially be useful in the local delivery of fisetin in 
lung-associated diseases, including acute lung injury and lung cancer, allowing dose 
reduction. The study may also provide an insight into the feasibility of a cyclodextrin 
complex as inhalable particles to deliver other insoluble anticancer agents via the pulmonary 
route. 
 
2. Materials and Methods 
2.1 Materials 
Fisetin (3,3’,4’,7-tetrahydroxyflavone) was purchased from Carbosynth Ltd. (Berkshire, UK) 
and SBE-β-CD (Captisol®) was a gift from Cydex Pharmaceuticals (La Jolla, USA). β-CD 
(Kleptose® DC, MW: 1135) and HP-β-CD (Kleptose® HP, MW: 1480) were gifts from 
Roquette Pharma (Northamptonshire, UK). L-leucine was purchased from EMD Chemicals 
Inc. (San Diego, USA) and absolute ethanol (99.9%) was procured from Fisher Scientific 
(Loughborough, UK). Acetonitrile, water, DMSO and trifluoroacetic acid (TFA) of HPLC 
grades and DPPH• (2,2-diphenyl-1-picrylhydrazyl) free radical, L-ascorbic acid and methanol 
of analytical grades were obtained from Sigma-Aldrich (Dorset, UK).  
The RPMI-1640 medium, fetal bovine serum and penicillin-streptomycin solution were 
purchased from Gibco (USA). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was obtained from Sigma (USA). 
2.2 Phase solubility study 
A phase solubility study was conducted according to the method of Higuchi and Connors [16] 
to investigate the influence of cyclodextrins on the solubilization of fisetin. An excess amount 
of fisetin was added into 5 mL deionized water containing different concentrations of β-CD, 
HP-β-CD and SBE-β-CD (0.156 to 10 mM). The mixture was mixed in a bath sonicator for 15 
min and left for further mixing at 100 rpm and 37°C for 24 h in an orbital incubator shaker. 
The uncomplexed fisetin was filtered from the solution using a 0.45 μm syringe filter. The 
filtrate was diluted accordingly and measured using HPLC.  
The concentration of solubilized fisetin (mM) was plotted against different 
concentrations of cyclodextrin (mM). The slope and y-intercept (So) of the straight lines were 
used to calculate the complexation parameters as follow; 
  
Stability constant, Ks  = [slope/ So (1-slope)]             Eq. (1)      
Complexation efficiency, CE  = slope/(1-slope)                       Eq. (2)   
2.3 Investigation of different complexation methods  
Complexation of fisetin with SBE-β-CD was carried out at a 1:1 molar ratio using two 
different methods of complexation; namely an aqueous method and a co-solvent method.  
In the aqueous method, fisetin and SBE-β-CD were dissolved in 10 mL deionized 
water and mixed in a bath sonicator for 15 min. The mixture was further mixed for 24 h in a 
shaking incubator at 80 rpm and 37°C.  
The co-solvent method involved solubilization of fisetin in 2 mL absolute ethanol and 
SBE-β-CD in 8 mL deionized water. The solutions were mixed and sonicated in a bath 
sonicator for 15 min prior to solvent evaporation under vacuum at 80°C, using a rotary 
evaporator (RC900, KNF Neuberger Ltd., UK). The dried complex was rehydrated with 
rotation at 80°C using 10 mL deionized water and left to cool to room temperature. In both 
methods, final solutions were filtered using a 0.45 µm syringe filter to separate the 
uncomplexed fisetin, and the filtrates were used for further studies. 
2.4 Investigation of different feed solution compositions for spray drying 
In Section 2.3, the co-solvent method was able to increase the amount of solubilized fisetin in 
the preparation. As the preparation was in solution, it was imperative to remove the organic 
solvent (i.e. ethanol) by rotary evaporation, and the complex was then rehydrated with water. 
As spray drying was introduced later to produce an inhalable powder, the ethanol could be 
removed by the process. An omission of evaporation and rehydration steps was considered an 
interesting approach, worth of investigation, to simplify the preparation steps. Therefore, the 
physical characteristic and in vitro aerosol deposition profile of the dry powders produced 
from two types of feed solutions (i.e. feed solution containing water and feed solution 
containing 20 %v/v ethanol in water) were investigated. 
Fisetin-SBE-β-CD complex was prepared using the co-solvent method containing 20 
%v/v ethanol in water and a 1:1 molar ratio of fisetin to SBE-β-CD. Fisetin and SBE-β-CD 
were dissolved in ethanol and deionized water, respectively, prior to a mixing in a bath 
sonicator for 15 min. The mixture was then treated differently to produce the two feed 
solutions for spray drying. For the feed solution containing 20 %v/v ethanol in water, the 
mixture was directly subjected to spray-drying. For the feed solution containing water alone, 
the mixture containing 20 %v/v ethanol in water was subjected to solvent evaporation under 
  
vacuum at 80°C using a rotary evaporator, to remove the ethanol. Then, the dried complex 
was rehydrated with deionized water for 10 min at 80°C and left to cool to room temperature. 
Both solutions in a final total powder mass of 0.4 %w/v were spray dried and the dried 
powder produced by both methods was immediately transferred to a desiccator at room 
temperature until further analysis. 
2.5 Incorporation of leucine as dispersibility enhancer 
Fisetin-SBE-β-CD complex solution containing 20 %v/v ethanol in water was prepared and 
leucine was added at a concentration of 5, 10 and 20 %w/w of the complex. The solution was 
stirred with magnetic stirring for 10 min, producing a final total powder mass of 0.4 %w/v in 
every formulation. The formulations were spray dried and stored in a desiccator at room 
temperature. 
2.6 Spray drying of the complexes 
Fisetin-SBE-β-CD complex solutions (0.4 %w/v) were spray dried using a mini laboratory 
spray dryer, model B-290 (Büchi Labortechnik, Switzerland) in an open-loop mode 
configuration using compressed air as the drying gas. The process was done under the 
following conditions: Inlet temperature (Tin): 120°C, corresponding to an outlet temperature 
(Tout): 66°C, spray gas flow: 536 L/h, pump: 20% (4.83 mL/min), aspirator: 100% (35 m
3
/h).   
 
2.7 Characterization of the preparations 
2.7.1 Determination of the amount of solubilized fisetin 
The amount of solubilized fisetin was determined by dissolving an accurately weighed sample 
of spray-dried powder in deionized water. The solution was vortexed for 5 s and filtered using 
0.45 μm syringe filter, to remove the uncomplexed fisetin. An aliquot of 30 µl of the 
appropriately diluted samples, before and after filtration, were injected into the HPLC to 
determine the amount of fisetin. The amount of solubilized fisetin was calculated according to 
the following equation; 
                             
                   Eq. (3) 
Solubilized fisetin (%) =           Amount of solubilized fisetin               x 100% 
                                         Total amount of fisetin in the formulation 
  
2.7.2 HPLC analysis  
The analysis was performed using an Agilent 1260 series HPLC system (Agilent 
Technologies, USA) equipped with quaternary pump VL, standard autosampler, thermostatted 
column compartment and variable wavelength detector VL. The data were acquired and 
analysed using OpenLab CDS ChemStation Edition (B.04.03) software. The chromatographic 
separation was performed using an ether-linked phenyl column with polar end-capping, 
Synergi
TM
 Polar-RP 80°A (250 x 4.6 mm i.d, 4 µm particle size).  
30µL samples were injected onto the column with a mobile phase comprising 
acetonitrile and 0.1 %v/v TFA in water, in the ratio of 30:70 (v/v). The chromatographic 
conditions were maintained at 40°C at a flow rate of 1.0 mL/min and a detection wavelength 
of 362 nm. The retention time of fisetin was found to be 8.45 min. The method was validated 
according to ICH guidelines [17] with a limit of detection (LOD) of 0.4 µg/mL and limit of 
quantification (LOQ) of 2 µg/mL. The method was linear in the range 2-60 µg/mL with a 
mean linear regression equation of y = 79.40 (±2.53)x – 22.93 (±15.50) from five calibration 
curves. The coefficient of determination, R
2
 was 0.9998 (±0.0002). The intra-day precision 
ranged from 0.34 to 1.26% while the accuracy ranged from -1.62 to -2.52%. The inter-day 
validation showed that all results were within the limit of ±5% [18], with the precision 
ranging from 2.94 to 3.20% and accuracy from 1.20 to 2.21%. 
2.7.3 Determination of in vitro antioxidant activity 
The antioxidant activity of free fisetin and the complex solutions was determined using the 
DPPH assay described previously [19,20]. Each sample was prepared in 5 or 6 different 
concentrations prior to the assay. Then, 1 mL of each concentration was added into 1 mL 
methanolic solution of DPPH• (100 µM) and the solutions were mixed by aspiration. An 
equal amount of deionized water was added into 1 mL DPPH• solution to serve as a control. 
The mixtures were incubated in the dark for 40 min prior to measurement in the UV 
spectrophotometer (Cary 100 UV-Vis, Agilent Technologies, USA) at 517 nm. The 
percentage inhibition was calculated as follows;  
  Inhibition (%) =  [(Abs Control – Abs Test)/Abs Control] x 100%           Eq. (4) 
The concentration at which the absorbance decreased by 50% (IC50) was determined 
from a linear correlation between concentration of fisetin (mM) against the inhibition (%) for 
all tested samples. The antioxidant assay for each sample was conducted in triplicate and the 
IC50 was compared to ascorbic acid as a standard. 
  
2.7.4 Determination of particle size distribution 
The particle size distribution of the dried powder was determined using a Sympatec HELOS 
BF laser diffraction analyzer (Sympatec GmbH, Clausthal-Zellerfeld, Germany) with 
RODOS/M dry powder disperser. The sample was loaded into a sealed sample tube and the 
tube was inserted into the micro-dosing device (ASPIROS). Sufficient sample was loaded to 
obtain an obscuration of more than 1 and each sample was measured in triplicate at an air 
pressure of 4 bar. Results were analysed using Windox 5 (version 5.7.0.0) software. 
 Results were analysed based on Mie Evaluation Extended (MIEE) algorithm for 
spherical, isotropic and homogenous particles, which transferred the scattered light data into 
particle size information. The complex refractive index value used in the analysis was 1.550, 
with air as continuous phase.   
 Results were expressed as the volume mean particle size and percentage undersize at 
10% (X10), 50% (X50) and 90% (X90). The X50 is also known as the volume median diameter 
(VMD) of the particles. The width of distribution was expressed as Span according to 
following equation; 
Span =  (X90 – X10)/X50                Eq. (5)                                                                        
2.7.5 Assessment of aerosol properties using the next generation impactor (NGI) 
The aerosol properties of the dry powders were evaluated using the NGI (Copley Scientific 
Limited, Nottingham, UK) conducted under pharmacopoeial conditions (Apparatus E, 
European Pharmacopoeia, Chapter 2.9.18). Air flow through the apparatus was adjusted to be 
at 60 ± 3 L/min using vacuum pump and two-way solenoid valve timer. The air flow rate was 
tested using a flow meter (DFM2000, Copley Scientific Limited, Nottingham, UK) prior to 
the testing.  
The central cup of the pre-separator insert was filled with 15 mL deionized water and 
the impaction cups were coated with 1 %v/v silicone oil in hexane before analysis. Powder 
samples (30 ± 1 mg) were accurately weighed and filled into no. 3 hard gelatine capsules and 
were individually loaded into the dosage chamber of an Aerolizer
®
 device (Novartis, Surrey, 
UK). The capsule was pierced and the Aerolizer
® 
was inserted into a mouth-piece adaptor. 
The powder was drawn into the NGI and tested for 4 s at 60 L/min. This was carried out using 
3 capsules for each sample. After all three actuations, powder in capsules, device, 
mouthpiece, induction port, and stages 1 to 8 of the NGI were collected with thorough rinsing 
using deionized water into separate volumetric flasks. The solutions were mixed in a bath 
sonicator for 15 min and appropriately diluted prior to fisetin determination using HPLC. 
  
 Under these conditions, the cut-off diameter for each NGI stage are; Stage 1: 8.06 µm, 
Stage 2: 4.46 µm, Stage 3: 2.82 µm, Stage 4: 1.66 µm, Stage 5: 0.94 µm, Stage 6: 0.55 µm, 
Stage 7: 0.34 µm and Stage 8 as terminal Micro-Orifice Collector (MOC) (Apparatus E, 
European Pharmacopoeia, Chapter 2.9.18). 
 The aerosolization parameters, including fraction recovered (FR), emitted dose (ED), 
fine particle dose (FPD) and fine particle fraction (FPF) were calculated as follows; 
 
                      Eq. (6) 
           Eq. (7) 
                        Eq. (8) 
          Eq. (9) 
Mass median aerodynamic diameter (MMAD) is determined as particle size at the 
50% of cumulative fraction by mass for the aerosolized powders. It is calculated from the 
graph of cumulative fraction against effective cut-off diameter on log probability axes. 
Geometric standard deviation (GSD) is a measure of the width of an aerodynamic particle size 
distribution. It is calculated using the same plot as for calculation of MMAD using following 
formula; 
                                 Eq. (10) 
2.7.6 X-ray powder diffraction (XRPD)  
XRPD analysis of samples was performed using a Rigaku MiniFlex 600 X-ray diffractometer 
(Rigaku, Japan) at room temperature. The Cu anode X-ray tube was operated at a generator 
voltage of 40 kV and a current of 15 mA. Diffraction patterns were recorded over diffraction 
angle (2θ) of 5-37°, a scanning rate of 5°(2θ)/min and scan step 0.05° (2θ). 
2.7.7 Fourier transform infrared (FT-IR) spectroscopy 
FT-IR analysis was undertaken using a Spectrum 100 FT-IR spectrometer (Perkin Elmer, 
Massachusetts, USA). Spectra were recorded over the range 4000-650 cm
-1
 with a resolution 
of 4 cm
-1
 and scanning speed of 0.2 cm/s.  
GSD = (d84/d16) 
1/2
                
 
FPF  =    Fine particle dose                            x 100% 
      Initial mass of fisetin loaded into the capsule 
 
FPD  =  Mass of fisetin on Stage 2 to Stage 8 
                
 
ED  =     Mass of fisetin from device to Stage 8   x 100% 
      Mass of fisetin from capsule to Stage 8 
 
FR  =       Mass of fisetin from capsule to Stage 8     x 100% 
     Initial mass of fisetin loaded into the capsule 
 
  
2.7.8 Thermogravimetric analysis (TGA) 
Residual solvent content of the spray-dried powders was determined using a 
thermogravimetric analyser (Discovery TGA, TA instrument, USA). Samples were loaded 
onto platinum pans and placed in sample holders. The analysis was carried out under a 
nitrogen purge of 20 mL/min. A heating rate of 10°C/min in the range of room temperature to 
400°C was applied to each sample and measurement was performed in triplicate.  
2.7.9 Scanning electron microscopy (SEM) 
A scanning electron microscope (SEM) was used to examine the surface morphology of 
produced powders. In the analysis, sample was placed on the surface of double-sided adhesive 
black carbon tabs which was attached to a 12.5 mm aluminium stub. The sample was sputter-
coated with gold (Quorum Q150R; Quorum Technologies Ltd., Sussex, UK) prior to 
observation under SEM (FEI Quanta 200F SEM; FEI, Eindhoven, Netherlands) at an 
acceleration voltage of 5 kV.  
2.8 In vitro cell toxicity of fisetin and the spray-dried formulation (MTT assay) 
The human lung adenocarcinoma cell line (A549) was used in the study. The cells were 
cultured in RPMI1640 with L-glutamine supplemented by 10 %v/v fetal bovine serum, 100 
µg/mL streptomycin and 100 U/mL penicillin. The cell cultures were maintained in an 
incubator at 37°C with humidified environment of 5% CO2 and 95% air. 
Cell viability was evaluated using the MTT assay. In brief, the cells were seeded in a 
density of 2 x 10
4
 cells per well in a 96-well plate and incubated for 24 h at 37°C (5% 
CO2/95% air). Then, 200 µL treatment solutions were added at different concentrations in the 
treated wells and 200 µL complete media solution was used in the untreated wells. The 
treatment solutions included fisetin, the spray-dried powder containing 20 %w/w leucine 
(SD_20%Eth20%Leu) and the blank formulation (containing SBE-β-CD and leucine), at 
concentrations of fisetin ranging from 4.7 to 600 µM. A stock solution of fisetin was prepared 
in DMSO and diluted accordingly with complete media while the SD_20%Eth20%Leu and 
the blank formulation were prepared and diluted using complete media. As fisetin samples 
contained DMSO, the cells were also treated with 0.1 %v/v DMSO in the media to evaluate 
the DMSO-derived cytotoxicity. After 48 h incubation, the medium was replaced with 110 µL 
MTT solution (0.45 mg/mL) and further incubated for 2 h. Then, the MTT solution was 
removed and the generated formazan was solubilized in 150 µL DMSO. The plate was shaken 
for 10 min prior to the optical density (OD) measurement using a multi-mode microplate 
  
reader (SpectraMax
®
 M2
e
, Molecular Devices, USA) at 570 nm. The percentage of cell 
viability was calculated as follows; 
 
 
Cell viability (%) =   OD of treated cells     x 100% 
                                            OD of untreated cells                                         Eq. (11) 
 
The cell viability curve was plotted and the effective concentration to kill 50% of the 
cells (EC50) was analysed using OriginPro
®
 2016 software (OriginLab Corporation, USA). 
2.9 Statistical analysis 
All parameters were statistically analysed using a t-test for independent group or one-way 
analysis of variance (ANOVA) with a post-hoc Tukey HSD test. For all analyses, differences 
were considered statistically significant when p < 0.05.   
 
3. Results and Discussion 
3.1 Phase solubility study 
A phase solubility plot of fisetin in three different cyclodextrins is shown in Fig. 1. The plot 
depicts a Higuchi AL type phase solubility behaviour for all complexes; a linear increase in 
solubility of fisetin with increasing concentration of cyclodextrins. Stability constant (Ks) is 
used to determine the solubilizing efficiency of cyclodextrins for a drug, as previously 
reported [19,20]. The solubilizing efficiency of fisetin in different cyclodextrins are in 
following order; SBE-β-CD > HP-β-CD > β-CD. The Ks value of fisetin in the β-CD system 
was in agreement with previous study of the complex in a neutral solution and 35°C which 
was 510 ± 30 M
-1
 [11]. The Ks values corresponded to a greater solubilization of fisetin at 10 
mM SBE-β-CD (4.474  ± 0.239 mM) compared to the systems containing HP-β-CD and β-
CD with values of 2.291 ± 0.046 and 0.628 ± 0.099 mM, respectively. All three complexes 
showed an increase in fisetin solubility in the aqueous solution compared to the free drug 
alone (0.1101 ± 0.0040 mM). Table 1 shows complexation parameters for all fisetin-
cyclodextrin complexes; 1:1 stoichiometry can be assumed as all slopes have values  below 1 
[21].  
Complexation efficiency (CE) describes the ratio between cyclodextrin complex and 
free cyclodextrins. This parameter is more reliable as it is independent of both the intrinsic 
solubility and the y-intercept [22]. The CE values showed comparable results to that of the Ks 
  
values. The corresponding molar ratio of fisetin to respective cyclodextrins shows that the 
best ratio was in SBE-β-CD system (i.e. 1 out of every 2 SBE-β-CD molecules forms a 
complex with fisetin). Lower molar ratio of drug to cyclodextrin is favoured as less 
cyclodextrin will be needed to form a soluble complex; thus reducing the bulkiness of the 
formulation. Thus, SBE-β-CD was chosen for further optimization with fisetin. 
3.2 Determination of antioxidant activity 
The antioxidant activities of fisetin in the complexes formed by all three cyclodextrins were 
compared to that of the fisetin solution (Fig. 2). There was no significant difference in the 
IC50 values (p > 0.05) suggesting that complexation with all cyclodextrins maintained the 
antioxidant activity of fisetin. Further, the solutions of free fisetin and fisetin-cyclodextrin 
complexes showed significantly lower IC50 values (p < 0.05) compared to ascorbic acid, 
suggesting better antioxidant activity in all fisetin-containing solutions. The DPPH assay was 
also conducted on blank cyclodextrin solution. The cyclodextrins did not show any inhibition 
in the DPPH activity up to 50 mM concentration, confirming that the antioxidant activity of 
all formulations was solely a function of the fisetin. 
3.3 Investigation of different complexation methods 
In the preparation of drug-cyclodextrin complexes, ethanol has been used as a solvent [23-
25]. In this study, ethanol alone could not be used as the solvent system as SBE-β-CD is not 
soluble in ethanol.  Co-solvency (i.e. addition of solvent into aqueous solution) can be used to 
enhance the complexation process as the solvent can help to increase solubility of a 
hydrophobic drug [22]. In a preliminary study, different ratios of ethanol and water were 
studied to find an optimum composition that would facilitate and enhance the complexation 
process. The ethanol content affected the stability of the formed complexes, with sub-optimal 
compositions resulting in precipitation of fisetin within 3 h of preparation. It has been 
reported ethanol content should be optimized, as too high solvent content reduces the 
inclusion of drug, as solvent will competitively bind to the cyclodextrin molecules [26]. In 
this study, this may cause the expulsion of fisetin from the cavity of cyclodextrin, causing 
precipitation. Thus, 20% v/v of ethanol in water was selected for the co-solvent method, 
based on optimal drug inclusion and minimal precipitation. 
The proportion of solubilised fisetin in complexes prepared using the aqueous and co-
solvent methods was 15.2 ± 1.1 and 90.2 ± 3.9 %, respectively, indicating that complexes 
  
produced by the co-solvent method had a 5.9-fold higher (p < 0.05) content of solubilized 
fisetin.  
 
3.4 Investigation of different feed solution compositions for spray drying 
3.4.1 Particle size distribution and residual solvent content 
The spray-dried powder produced from a feed solution containing water alone (SD_H2O) 
showed a unimodal particle size distribution (Fig. 3A) with all particles below the size of 5 
µm. The particles showed a narrow size distribution with an X50 value of 1.50 ± 0.18 µm and 
Span value of 1.55 ± 0.25.  
The spray-dried powder produced from a feed solution containing 20 %v/v ethanol 
(SD_20%Eth) displayed a bimodal size distribution with a group of particles having a mode 
less than 3 µm, and another population of particles in the size range: approximately 3 to 20 
µm probably indicating agglomeration of smaller particles. The wider particle size 
distribution resulted in a Span value of 3.14 ± 0.51, though the X50 value was 1.48 ± 0.08 µm.  
The formulations showed no difference (p > 0.05) in the residual solvent contents, 
with values of 7.75 ± 0.37% for the powder produced from feed solution containing water and 
8.31 ± 0.53% for the powder produced from feed solution containing 20 %v/v ethanol. The 
residual solvent content of spray-dried powders varies between formulations, with some 
reports of ~3% [27] and others between 6 to 11% [28,29]. The residual solvent content 
depends on the hygroscopicity of the material. Evaporation of the solvent molecules in the 
drying chamber of the spray dryer will cause an increase in the vapour concentration within 
the instrument. A hygroscopic material will tend to take up more water during the spray-
drying process causing a higher residual solvent content in the final powder formulation [28]. 
SBE-β-CD 7 that was used in the study has shown to be hygroscopic and adsorb more 
moisture compared to other substituted SBE-β-CD (i.e. SBE-β-CD 4 and 5; the number 
indicates the average number of substituted sulfobutyl ether groups per CD) [30]. Thus, 
giving a high residual solvent content. 
Despite that, the powders were able to be dispersed during the measurement in laser 
diffraction analyzer and NGI, giving a sufficient particle size distribution and FPF.  
3.4.2 FT-IR analysis 
The infrared spectra of all samples are presented in Fig. 4. The fisetin crystal showed a 
characteristic O-H stretch at 3344.18 and 1205.94 cm
-1
. These peaks are still evident in the 
  
spectrum of a physical mixture of fisetin and SBE-β-CD, showing that the drug remained in 
its crystalline state without any complexation. However, the peaks are absent on the spectra of 
spray-dried formulations indicating restriction of vibration and bending of fisetin molecules in 
the host cavity of the inclusion complex. This result is in agreement with a previous study of a 
SBE-β-CD-drug complex [31]. SBE-β-CD had a broad peak at 3382.94 cm-1, which indicates 
O-H stretch of the alcoholic group in the molecule. It also has a C-H stretch of the alkane 
group at 2928.98 cm
-1
. These peaks are less obvious in the spectrum of the physical mixture 
but can be clearly seen in the spectra of spray-dried formulations. No new peaks were seen in 
the spectra of the complex, indicating no chemical interaction between fisetin and SBE-β-CD 
molecules. The host-guest complex is reported to depend on hydrophobic interaction between 
lipophilic cavity of cyclodextrin and the drug, without formation or breakage of covalent 
bonds [32]. 
3.4.3 XRPD analysis 
The diffractogram of pure fisetin (Fig. 5) indicated a typical crystalline nature with a large 
number of sharp diffraction peaks especially at 12.35, 15.50, 24.05, 26.25 and 28.25° (2θ). 
The spray-dried fisetin powder from 20 %v/v ethanol solution showed a lower degree of 
crystallinity and low intensities peaks, indicating the presence of a mixture of amorphous and 
crystalline state in the preparation. In contrast, broad and diffused peaks with low intensities 
were recorded for pure SBE-β-CD indicating its amorphous state. Some diffraction peaks 
from the crystalline fisetin are visible on the diffractogram of the physical mixture (labelled 
with arrows), but with lower intensities as fisetin was diluted with SBE-β-CD. The peaks are 
not present in the spray-dried formulation from both methods, suggesting the formation of 
fisetin-SBE-βCD complexes in the amorphous form.  
3.4.4 In vitro aerosol deposition study 
In the NGI, an air flow of 60 L/min was used, as in previous impactor studies of 
spray-dried powders [33,34]. Fig. 6 shows the distribution of fisetin in the NGI. The spray-
dried powder produced from a feed solution containing 20 %v/v ethanol showed improved 
aerosolization, based on lower deposition in the capsules to pre-separator stage but higher 
deposition in Stage 2 onwards compared to powder produced from a feed solution in water. 
Table 2 shows the aerosol properties for both formulations calculated from the NGI 
deposition results. The powder which was produced from a feed solution containing 20 %v/v 
ethanol had a higher fine particle fraction (FPF) compared to spray-dried powder produced 
  
from a feed solution containing water alone. The powder produced from 20% ethanol also 
showed a 2-fold increase (p < 0.05) in the fine particle dose (FPD). In this study, almost 100% 
of fisetin loaded into the capsules was recovered which meets the requirements by European 
Pharmacopoeia (75 to 125%). Approximately 90% of fisetin was successfully emitted from 
the capsules for both formulations. The MMAD and GSD for both formulations were similar 
(p > 0.05). However, the MMADs for both formulations were significantly higher (p < 0.05) 
than the values of volume median diameter (X50), suggesting that the particles may not be 
optimally dispersed during aerosolization.  
3.4.5 SEM analysis 
Fig. 7 shows scanning electron micrographs of all powders. The spray-dried fisetin powder 
from 20 %v/v ethanol solution (Fig. 7A) had spherical particles with the appearance of fisetin 
crystals on the surface. This corresponds with the XRPD result showing a mixture of both 
amorphous and crystalline state in the preparation. Particles of the spray-dried SBE-β-CD 
powder from the same solvent composition were spherical in form (Fig. 7B). The fisetin’s 
crystals were not apparent in the SEM images of the spray-dried fisetin-SBE-β-CD powders 
(Fig. 7C and D), confirming the amorphosity of the preparations.  
The spray-dried powders from the feed solution containing water alone comprised 
pitted spherical particles (Fig. 7C). The majority of the particles were approximately 2 µm in 
diameter. The spray-dried powders from the feed solution containing 20 %v/v ethanol also 
showed pitted spherical morphology, but with greater variation in size (Fig. 7D). The pitted 
morphology of the particles was more evident compared to the spray-dried powder from feed 
solution containing water, possibly suggesting a hollower internal structure. The difference in 
the evaporation rate between water and ethanol during spray-drying may contribute to the 
production of such particles. This may also indicate lower density of the particles. The 
powder produced was fluffier and lighter compared to the powder produced from feed 
solution containing water. This may explain the higher FPF observed in the formulation, as 
powder with lower density may move more readily to the lower stages of the NGI.  
 
3.5 Incorporation of leucine as a dispersibility enhancer 
3.5.1 Particle size distribution and residual solvent content 
The spray-dried formulation from the feed solution containing 20 %v/v ethanol (SD_20%Eth) 
was chosen for further investigation by adding leucine as a dispersibility enhancer. This 
  
formulation was chosen as it gave better aerosolization properties compared to the spray-dried 
formulation from the feed solution containing water alone (SD_H2O).  
Addition of leucine into the spray-dried formulation changed the particle size 
distribution of the powder from bimodal to unimodal distribution, regardless of the amount of 
leucine added (Fig. 3B). The same change in the particle size distribution has been reported 
with the addition of 10 %w/w of leucine in the initial solution of a non-viral gene therapy 
formulation [35]. Incorporation of leucine as low as 5 %w/w has also been shown to reduce 
the cohesiveness and improve the flowability of spray-dried herbal extract powder [27]. The 
improvement in the flowability is shown by Span values presented in Table 3. Addition of 
leucine caused a reduction in Span value (p < 0.05) from 3.14 in the formulation without 
leucine, to the lowest value of 1.22 in the formulation with 20 %w/w leucine.   
Table 3 shows that incorporation of leucine as low as 5 %w/w reduced the volume 
median diameter (X50) from 1.48 ± 0.08 to 1.25 ± 0.01 µm (p < 0.05). Further, addition of 
leucine into the formulation did not affect formation of the fisetin-SBE-β-CD complex as 
shown by the same percentage of solubilized fisetin. At least 10 %w/w leucine was needed to 
significantly reduce (p < 0.05) the residual solvent content from 8.31 to 6.64%. The additional 
increase in the amount of leucine to 20 %w/w did not further reduce the residual solvent 
content (p > 0.05).  
The spray-dried formulation containing 20 %w/w leucine, showed an increase in the 
aqueous solubility of fisetin from 31.51 ± 1.16 µg/mL to 1006.19 ± 37.08 µg/mL. 
3.5.2 XRPD analysis 
Fig. 5 shows diffractograms of raw materials and spray-dried powders with leucine. The 
diffractograms of spray-dried complexes containing leucine showed the disappearance of 
fisetin’s and leucine’s crystalline peaks, confirming that the formulations were in the 
amorphous form. 
3.5.3 In vitro aerosol deposition study 
An increase in the amount of leucine resulted in a significant reduction (p < 0.05) in the 
deposition of fisetin especially in capsules, device and mouthpiece stages (Fig. 6). An 
increase in the deposition of fisetin in Stage 2 to Stage 8 was also seen, though most of the 
increases for individual stages were not significant (p > 0.05), with the highest deposition 
seen in formulation containing 20 %w/w leucine.  
  
The fraction recovered and MMAD were not influenced by the presence of leucine 
(Table 2). However, the MMAD values of all preparations were significantly higher (p < 
0.05) than their respective volume median diameters (X50). This suggests that the particles act 
as aggregates during aerosolization, and were not completely dispersed.  
The emitted dose from the capsules was improved in formulations containing 10 and 
20 %w/w leucine. The value increased (p < 0.05) from 88.08% without the presence of 
leucine to 97.31% in the formulation containing 20 %w/w leucine. This may be caused by the 
low residual solvent content in both formulations compared to the formulation without leucine 
(Table 3). Low residual solvent content may reduce the adhesive interaction between capsule 
wall and particles thus increasing the number of particles emitted into the NGI. This may 
explain reduction in the amount of fisetin in capsules during the deposition study in NGI (Fig. 
6).  
An increase in FPF was found for formulations containing 10 and 20 %w/w leucine. 
The value increased from 32.49 ± 2.46% in formulation without leucine to 49.41 ± 9.01% in 
formulation with 10 %w/w leucine (p < 0.05). An increase in the amount of leucine to 20 
%w/w caused further improvement in the FPF to 75.83 ± 3.34% (p < 0.05). Addition of 20 
%w/w leucine increased the FPD from 3.76 mg in the formulation without leucine, to 7.06 mg 
(p < 0.05). 
3.5.4 SEM analysis 
The SEM images showed that incorporation of leucine into the formulation, at a concentration 
of as low as 5 %w/w caused an alteration in the morphology, giving a wrinkled spherical 
shaped particle. The wrinkled and rough surface becomes more pronounced with increased 
leucine content (Fig. 7E, F and G). The change in morphology can be explained by the 
enrichment of leucine on the surface of the particles. Leucine has a hydrophobic nature and 
has a tendency to act as a weak surfactant [36], which causes an accumulation of leucine at 
air-solution interfaces leading to enrichment of the amino acid on particle surfaces during 
spray-drying [27]. This forms a leucine film that collapses when solvent is removed by 
evaporation, thus forming the observed surface.   
3.6 In vitro cell toxicity of fisetin and the spray-dried formulation 
The A549 cell viability curve is shown in Fig. 8. The blank formulation, containing SBE-β-
CD and leucine, showed no cytotoxic activity at all investigated concentrations (up to 495 µM 
for SBE-β-CD and 2313 µM for leucine). The cells also showed no DMSO-derived 
  
cytotoxicity at a concentration of 0.1 %v/v DMSO in the media. Fisetin and the formulation 
containing 20 %w/w leucine (SD_20%Eth20%Leu) showed a similar growth inhibition curve 
with no significant difference (p < 0.05) in the cytotoxic activity. The EC50 value of fisetin 
and SD_20%Eth20%Leu preparation were 67.97 ± 14.48 and 75.86 ± 18.11 µM, respectively. 
The result shows that complexation with SBE-β-CD and spray-drying process did not alter the 
cytotoxicity of fisetin in the A549 cell line.  
 
4. Conclusion 
This study has shown that complexation with SBE-β-CD was able to enhance the solubility of 
fisetin without altering its in vitro antioxidant activity. Spray drying of the complex in an 
aqueous solution containing ethanol as a co-solvent produced a low density powder with 
better aerosolization properties than a powder produced from complexes in water alone. 
Further, addition of leucine into the preparation generated a powder with improved 
flowability, FPF and FPD. The spray-dried complexed preparations showed an unchanged 
cytotoxic activity of fisetin against the A549 cell line. In conclusion, the dry powder 
inhalation of fisetin-SBE-β-CD complex may provide an improvement in the solubility of 
fisetin and be capable of delivering high amount of fisetin to the deep lung region for 
therapeutic applications. Although fisetin may not be the best candidate for pulmonary 
delivery because of the relatively high doses needed, this study demonstrates how its 
formulation and delivery can be optimised and provides data that can be applied to other 
potential anti-cancer agents. Additionally, synergistic combination of fisetin with other anti-
cancer agent may be explored for pulmonary delivery using a SBE-β-CD complex.  
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Fig. 1. Phase solubility plots of fisetin in different cyclodextrins, n = 3 ± s.d. 
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Fig. 2. IC50 values of fisetin, fisetin-cyclodextrin complexes and ascorbic acid, n = 3 ± s.d., 
 *p < 0.05.
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Fig. 3. 
Particle size distributions of spray-dried powders (A) from different feed solutions and (B) in 
the presence of different contents of leucine. 
  
 
                  
Fig. 4. FT-IR spectra of raw materials, physical mixture and spray-dried formulations of 
fisetin-SBE-β-CD complex (SD_H2O and SD_20%Eth). 
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Fig. 5. XRPD diffractograms of raw materials, spray-dried fisetin (SD_Fisetin), physical 
mixture and spray-dried complexes. 
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Fig. 6. Distribution of spray-dried powder preparations of fisetin in the NGI, n = 3 ± s.d, *significant difference compared to SD_20%Eth, p < 
0.05. 
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Fig. 7. Scanning electron micrographs of spray-dried (A) fisetin, (B) SBE-β-CD, spray-dried fisetin-SBE-β-CD complex from feed solutions 
containing (C) water and (D) 20 %v/v ethanol; in the presence of (E) 5 %w/w, (F) 10 %w/w and (G) 20 %w/w leucine; magnification: 20K. 
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Fig. 8. Cell viability (%) of A549 cells after the treatment with fisetin, SD_20%Eth20%Leu 
preparation and blank formulation (containing SBE-β-CD and leucine) after 48 h, n = 3 ± s.d.
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Table 1  
Complexation parameters of fisetin in different types of cyclodextrin. Mean ± s.d., n = 3. 
System Slope 
y-intercept, So 
(mM) 
Stability constant, 
Ks (M
-1
) 
R
2 
Complexation 
efficiency, CE 
Molar ratio 
(Fisetin : CD) 
β-CD 0.052 ± 0.009 0.114 ± 0.009 481.66 ± 67.38 0.9939 ± 0.0026 0.055 ± 0.010 1 : 19 
HP-β-CD 0.217 ± 0.001 0.171 ± 0.029 1647.25 ± 264.88 0.9942 ± 0.0045 0.277 ± 0.002 1 : 5 
SBE-β-CD 0.432 ± 0.019 0.184 ± 0.009 4138.84 ± 199.27 0.9985 ± 0.0007 0.763 ± 0.058 1 : 2 
 
  
Table 2  
Aerosolization properties of the spray-dried powders. Mean ± s.d., n = 3. 
Preparation FR (%) ED (%) FPF
a
 (%) FPD (mg)  MMAD (µm) GSD 
SD_H2O 96.49 ± 1.07 91.01 ± 2.12 16.59 ± 2.65
* 
1.88 ± 0.35
* 
2.35 ± 0.37 1.68 ± 0.03 
SD_20%Eth 98.89 ± 5.43  88.08 ± 1.29 32.49 ± 2.46 3.76 ± 0.27 2.45 ± 0.32 1.75 ± 0.07 
SD_20%Eth5%Leu 105.64 ± 4.81 92.54 ± 1.80 38.67 ± 2.73 4.60 ± 0.17 2.34 ± 0.16 1.75 ± 0.02 
SD_20%Eth10%Leu 108.02 ± 2.95 94.73 ± 2.56
*
 49.41 ± 9.01
*
 5.66 ± 0.91
*
 2.54 ± 0.08 1.72 ± 0.02  
SD_20%Eth20%Leu 98.80 ± 0.93 97.31 ± 0.74
*
 75.83 ± 3.34
*
 7.06 ± 0.30
*
 2.11 ± 0.01 1.73 ± 0.12 
FR: Fraction recovered, ED: Emitted dose, FPF: Fine particle fraction, FPD: Fine particle dose, MMAD: Mass median aerodynamic diameter, 
GSD: Geometric standard deviation. 
a
 fraction of particles less than 4.46 µm. 
*
 significant difference compared to SD_20%Eth, p < 0.05. 
  
Table 3  
Physical properties of spray-dried complexes in the presence of leucine. Mean ± s.d., n = 3. 
Preparation 
Particle size (µm) Solubilized 
fisetin (%) 
Residual  
solvent (%) X50 Span 
SD_20%Eth 1.48 ± 0.08 3.14 ± 0.51  96.8 ± 5.0 8.31 ± 0.53  
SD_20%Eth5%Leu 1.25 ± 0.01
*
 1.33 ± 0.05
*
 96.3 ± 0.9 7.27 ± 0.49 
SD_20%Eth10%Leu 1.24 ± 0.05
*
 1.27 ± 0.02
*
 97.6 ± 0.4 6.64 ± 0.56
*
 
SD_20%Eth20%Leu 1.23 ± 0.04
*
 1.22 ± 0.02
*
 98.8 ± 0.8 6.05 ± 0.66
*
 
*
 significant difference compared to SD_20%Eth, p < 0.05. 
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